# US 2025/0152606 A1 · Induction of irreversible infertility in female mammalian animals using a single progesterone implant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152606 A1
- Document ID: US20250152606A1
- Status: Published application
- Kind: A1
- Application number: 18/838,623
- Filed: 2023-02-17
- Published: 2025-05-15
- Earliest claimed: 2022-02-18
- Assignees: The Board of Trustees of the University of Illinois; Epivara
- Applicants: The Board of Trustees of the University of Illinois; Epivara
- Inventors: CheMyong KO; Po-Ching LIN; Chan Jin PARK
- Web page: https://patentgrep.com/patent/US20250152606A1

## CPC

- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 15/18: Feminine contraceptives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The described technology induces sterility in female animals by a single injection of progestin containing implants formulated to elevate progesterone level for an extended period to neonatal animals. The sterilant can be progesterone or its derivatives which can activate progesterone receptors. Such formulation may be achieved by using a biodegradable copolymer that releases progesterone for more than 10 days. The progesterone-containing implant can be injected intramuscularly, subcutaneously, or intraperitoneally. The progesterone released from the implants over an extended period then prevents the development of uterine glands, thereby irreversibly sterilizing the female animals.

## Claims

### Claim 1

A method for inducing permanent sterility comprising implanting a single slow-release formulation of progesterone (P4) into a neonatal female mammal, wherein the slow-release formulation maintains an elevated serum P4 level in the neonatal female mammal for more than 10 days above a normal P4 serum level for a control neonatal female mammal to permanently inhibit uterine gland development throughout the natural life span of the neonatal female mammal, thereby inducing permanent sterility.

### Claim 2 (depends on 1)

The method of claim 1 wherein the neonatal female mammal is about 2 days of age to about 30 days of age.

### Claim 3 (depends on 1)

The method of claim 1 wherein the elevated serum P4 level is greater than the normal P4 serum level by about 2-fold or more.

### Claim 4 (depends on 1)

The method of claim 1 wherein the elevated serum P4 level is greater than the normal P4 serum level by about 2-fold to about 5-fold.

### Claim 5 (depends on 1)

The method of claim 1 wherein the elevated serum P4 level is maintained at about 10 ng/ml to about 50 ng/ml.

### Claim 6 (depends on 1)

The method of claim 1 wherein the elevated serum P4 level in the neonatal female mammal is maintained for more than 10 days.

### Claim 7 (depends on 1)

The method of claim 1 wherein the elevated serum P4 level in the neonatal female mammal is maintained for about 10 days to about 30 days.

### Claim 8 (depends on 1)

The method of claim 1 wherein the slow-release formulation comprises about 10 wt. % to about 97 wt. % P4.

### Claim 9 (depends on 1)

The method of claim 1 wherein the slow-release formulation comprises about 1 mg to about 50 mg of P4.

### Claim 10 (depends on 1)

The method of claim 1 wherein the slow-release formulation comprises P4 and a biodegradable polymer that has been formed into microspheres.

### Claim 11 (depends on 10)

The method of claim 10 wherein the wherein the biodegradable polymer comprises polylactic-co-glycolic acid (PLGA).

### Claim 12 (depends on 10)

The method of claim 10 wherein the microspheres are mixed with an aqueous solution and the mixture is injected subcutaneously into the neonatal female mammal.

### Claim 13 (depends on 1)

The method of claim 1 wherein the slow-release formulation comprises P4 and a polydimethylsiloxane capsule.

### Claim 14 (depends on 13)

The method of claim 13 wherein the P4 is encased in the polydimethylsiloxane capsule and the dimensions of the capsule are about 0.5 mm to about 1.5 mm i.d., about 1.5 mm to about 2.5 mm o.d., and about 2 mm to about 10 mm in length.

### Claim 15 (depends on 13)

The method of claim 13 wherein the capsule is implanted subcutaneously into the neonatal female mammal.

### Claim 16

A method for inducing permanent sterility in a female canine comprising implanting a slow-release formulation of progesterone (P4) into a neonatal female canine, wherein the slow-release formulation maintains an elevated serum P4 level of at least 20 ng/ml in the neonatal female canine for more than 10 days to permanently inhibit uterine gland development throughout the natural life span of the neonatal female canine, thereby inducing permanent sterility.
